Translational Research
Volume 154, Issue 4 , Pages 194-201 , October 2009

Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease

  • Luca Miele

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Alessandra Forgione

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Giuseppe La Torre

      Affiliations

    • Institute of Public Health (Biostatistics Unit), Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Vittoria Vero

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Consuelo Cefalo

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Simona Racco

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Valerio G. Vellone

      Affiliations

    • Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Fabio M. Vecchio

      Affiliations

    • Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Giovanni Gasbarrini

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Gian Lodovico Rapaccini

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • ,
  • Manuela G. Neuman

      Affiliations

    • In Vitro Drug Safety and Biotechnology Laboratory, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Antonio Grieco

      Affiliations

    • Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
    • Corresponding Author InformationReprint requests: Antonio Grieco, MD, Department of Internal Medicine, Agostino Gemelli University Hospital, School of Medicine, Catholic University of Rome, 8 Largo Agostino Gemelli - 00168 Rome, Italy

Received 15 January 2009 ,Revised 18 June 2009 ,Accepted 20 June 2009.

References 

  1. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–1123
  2. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756–761
  3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231
  4. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98:2060–2063
  5. Geerts A. History, heterogeneity developmental biology and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:311–337
  6. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006;55:1650–1660
  7. Pessayre D, Larrey D, Biour M. Drug induced liver injury. In:  Bircher J,  Benhamou JP,  McIntyre N,  Rizzetto M,  Rodes J editor. Oxford textbook of clinical hepatology. Oxford, UK: Oxford University Press; 1999;
  8. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017–1044
  9. Colman P, Thomas D, Zimmet P, Welborne T, Garcia-Webb P, Moore M. New classification and criteria for diagnosis of diabetes mellitus. MJA. 1999;170:375–378
  10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on dectection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–1725
  12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  13. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321
  14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BA. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474
  15. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46
  16. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316:1236–1238
  17. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292
  18. Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology. 1998;114:842–845
  19. Leclerque IA. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis?. Clinical Science. 2004;106:235–237
  20. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 2005;54:303–306
  21. Shuppan D, Ruehl D, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Disease. 2001;21:351–373
  22. Arthur MJ. Collagenases and liver fibrosis. J Hepatol. 1995;22:43–48
  23. Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta. 1993;218:47–58
  24. Murawaki Y, Ikuta Y, Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta. 1999;281:109–120
  25. Muzzillo DA, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y, et al. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol. 1993;8:437–441
  26. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1—possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology. 2002;49:1369–1372
  27. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935–942
  28. Ueno T, Tamaki S, Sugawara H, et al. Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases. J Hepatol. 1996;24:177–184
  29. Maruyama K, Feinman L, Fainsilber Z, Nakano M, Okazaki I, Lieber CS. Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis. Life Sci. 1982;30:1379–1384
  30. Montfort I, Perez-Tamayo R, Alvizouri AM, Tello E. Collagenase of hepatocytes and sinusoidal liver cells in the reversibility of experimental cirrhosis of the liver. Collagenase of hepatocytes and sinusoidal liver cells in the reversibility of experimental cirrhosis of the liver. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59:281–289
  31. Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49:7–19
  32. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–156
  33. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362
  34. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255–259
  35. Yoneda M, Mawatari H, Fujita K, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–381
  36. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology. 2005;41:64–71
  37. Ramadori G, Zöhrens G, Manns M, et al. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest. 1991;21:323–330
  38. Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114–125
  39. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713
  40. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–460
  41. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72–81
  42. Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. J Hepatol. 1998;28:439–446
  43. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?. Ann Clin Biochem. 2005;42:441–447
  44. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Noninvasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006;26:864–871
  45. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase- 1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. 2002;277:11069–11076

 Supported by Grant Cofin Miur-Università Cattolica “Giovani Ricercatori 2002” (to L.M.) and by Grant Miur-Università Cattolica Linea D.1. 2004 (to A.G.).

PII: S1931-5244(09)00183-2

doi: 10.1016/j.trsl.2009.06.007

Translational Research
Volume 154, Issue 4 , Pages 194-201 , October 2009

Article Tools

* Image Usage & Resolution